Over the last 7 days, the United States market has experienced a 2.1% drop, yet it remains up by 19% over the past year with earnings forecasted to grow by 17% annually. In this context of fluctuating market conditions, growth companies with high insider ownership can offer unique insights into potential opportunities as they often reflect strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	34.3%	69.4%
Upstart Holdings (UPST)	13.9%	66.5%
Precigen (PGEN)	11.7%	55.4%
Karman Holdings (KRMN)	14.9%	54%
Hinge Health (HNGE)	16.3%	27.1%
Himax Technologies (HIMX)	29.2%	70.2%
Dave (DAVE)	17.2%	23%
Carlyle Group (CG)	27.5%	20.5%
Astera Labs (ALAB)	10%	33.2%
Almonty Industries (ALM)	10.8%	37.1%

Let's dive into some prime choices out of the screener.

Corcept Therapeutics (CORT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of $13.09 billion.

Operations: The company's revenue is derived from the discovery, development, and commercialization of pharmaceutical products, amounting to $830.81 million.

Insider Ownership: 10.8%

Earnings Growth Forecast: 43% p.a.

Corcept Therapeutics is experiencing significant growth, with earnings forecasted to increase at 43% annually, outpacing the US market. Despite substantial insider selling recently, the company remains undervalued by 61% compared to its estimated fair value. Recent developments include increased revenue guidance for 2026 to US$1.1 billion-US$1.2 billion and positive clinical trial outcomes for its treatments in hypercortisolism and ovarian cancer, although profit margins have declined from last year.

BillionToOne (BLLN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BillionToOne, Inc. is a precision diagnostics company that focuses on quantifying biology to develop molecular diagnostics, with a market cap of $4.50 billion.

Operations: The company's revenue primarily comes from its Medical Labs & Research segment, totaling $397.41 million.

Insider Ownership: 10.7%

Earnings Growth Forecast: 31.1% p.a.

BillionToOne is poised for strong growth, with earnings projected to rise significantly above the US market average. The company recently turned profitable and reported substantial revenue increases, forecasting annual sales between US$450 million and US$465 million for 2026. Despite a volatile share price, it trades below its estimated fair value. Recent advancements include expanding its prenatal screening portfolio and appointing a new Chief Medical Officer to enhance its oncology offerings.

Precigen (PGEN)

Simply Wall St Growth Rating: ★★★★★★

Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $2.56 billion.

Operations: Precigen's revenue primarily comes from its biotechnology startups segment, which generated $85.72 million.

Insider Ownership: 11.7%

Earnings Growth Forecast: 55.4% p.a.

Precigen has shown remarkable growth, with recent earnings revealing a significant revenue increase to US$54.98 million in Q2 2026 from US$0.856 million a year prior, alongside turning profitable with a net income of US$20.07 million. Despite being dropped from several Russell indices, its FDA-approved therapy PAPZIMEOS strengthens its market position. Analysts forecast robust revenue and profit growth over the next few years, though insider trading activity remains mixed without substantial buying or selling recently.

Key Takeaways

• Click through to start exploring the rest of the 182 Fast Growing US Companies With High Insider Ownership now.
• Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 23 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.